Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
12. Juni 2024 08:00 ET
|
Quoin Pharmaceuticals, Inc.
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles...
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
09. Mai 2024 08:30 ET
|
Quoin Pharmaceuticals, Inc.
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into...
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
02. Mai 2024 16:10 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
13. März 2024 16:05 ET
|
Quoin Pharmaceuticals, Inc.
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical...
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
07. März 2024 16:05 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
05. März 2024 08:00 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
04. März 2024 08:00 ET
|
Quoin Pharmaceuticals, Inc.
Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment...
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
08. Februar 2024 08:00 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company exclusively focused on the development and...
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
13. Dezember 2023 08:30 ET
|
Quoin Pharmaceuticals, Inc.
Positive initial data and clean safety profile catalyze optimization planSize of both ongoing clinical trials significantly increasedLower dose eliminated from blinded trialDosing frequency changed to...
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
08. November 2023 17:46 ET
|
Quoin Pharmaceuticals, Inc.
Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were observed across a number of clinical...